RxDoctor Payments DataLook up a doctor →

John Campbell, MD

Infectious Disease · Chesterfield, MONPI 1740395474

Payments from drug & device makers

$10,547in general payments, 2019–2025

Across 572 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • AbbVie$960
  • Johnson & Johnson$935
  • Gilead$869
  • Merck$776
  • Amgen$694
  • plus $5K from 44 others

What the payments were for

  • Speaking & faculty fees$741%
  • Food & beverage$10,30398%
  • Education$1702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,547 in reported general payments places this provider in the 85th percentile of 177 infectious disease providers in Missouri.

See all infectious disease providers in Missouri

Medicare billing

Part B allowed, 2024
$77,343
Medicare patients
358
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi71$277,447
BiktarvyBictegrav/Emtricit/Tenofov Ala62$245,199
GenvoyaElviteg/Cob/Emtri/Tenof Alafen36$141,027
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$97,576
PrezcobixDarunavir/Cobicistat28$70,494
DovatoDolutegravir Sodium/Lamivudine21$67,779
VemlidyTenofovir Alafenamide27$39,489
DescovyEmtricitabine/Tenofov Alafenam15$37,237
IsentressRaltegravir Potassium19$35,433
PifeltroDoravirine16$32,624
Maraviroc13$9,858
EliquisApixaban16$8,095
MyrbetriqMirabegron21$4,755
Tadalafil16$4,300
Opium Tincture11$2,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Vemlidy, Descovy$869$462,951140 claims
Viiv Healthcare CompanyTriumeq, Dovato$1,595$345,22792 claims
Johnson & JohnsonPrezcobix$935$70,49428 claims
MerckIsentress, Pifeltro$776$68,05735 claims
PfizerEliquis$284$8,09516 claims
Astellas Pharma US IncMyrbetriq$164$4,75521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 infectious disease providers in Missouri.

Other infectious disease in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →